Extended indication Extension of indication to include patients from 1 month to 4 years of age for the Briviact treatmen
Therapeutic value No estimate possible yet
Registration phase Registration application pending

Product

Active substance Brivaracetam
Domain Neurological disorders
Reason of inclusion Indication extension
Main indication Epilepsy
Extended indication Extension of indication to include patients from 1 month to 4 years of age for the Briviact treatment, as a consequence.
Proprietary name Briviact
Manufacturer UCB
Route of administration Oral
Therapeutical formulation Tablet
Budgetting framework Intermural (MSZ)
Additional comments Sodium channel antagonist; SV2A protein modulator.

Registration

Registration route Centralised (EMA)
ATMP No
Submission date January 2021
Expected Registration October 2021
Registration phase Registration application pending

Therapeutic value

Therapeutic value No estimate possible yet

Expected patient volume per year

There is currently nothing known about the expected patient volume.

Expected cost per patient per year

There is currently nothing known about the expected cost.

Potential total cost per year

There is currently nothing known about the possible total cost.

Off label use

There is currently nothing known about off label use.

Indication extension

There is currently nothing known about indication extensions.

Other information

There is currently no futher information available.